A team from Mount Sinai and Swift Biosciences used targeted sequencing to detect cancer mutations in uterine lavage fluid.
The partners plan to improve yields from small input samples and provide better sequencing libraries.
Both partners believe the agreement will help expand the scope of their services and give them additional markets for their products.
The companies will combine their technologies to create workflows for the next-generation sequencing of tumor cells obtained from FFPE samples.
The companies are combining their respective products to provide a solution that covers genetic testing from sample prep to clinical reports.
Swift will incorporate Horizon Discovery's NGS reference standards as a positive control in its oncology panel.
Researchers hope that newfound genetic information will help conservation efforts for the vaquita porpoise.
The jointly developed workflow uses Fluxion's IsoFlux system for circulating tumor cell enrichment along with Swift's Accel-Amplicon technology.
Agilent Technologies has optimized its SureSelect Target Enrichment solution for Life Technologies' Ion Proton.
NEW YORK (GenomeWeb News) – Swift Biosciences today said it has completed a Series B financing round that raised $7 million.
In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.
The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.
A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.
Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.